Medicinal Chemistry
Title:Meet Our Editorial Board Member
Volume: 13 Issue: 3
Author(s): Fazlul Huq*
Affiliation:
- Sydney Medical School The University of Sydney Sydney,Australia
Export Options
About this article
Cite this article as:
Huq Fazlul*, Meet Our Editorial Board Member, Medicinal Chemistry 2017; 13 (3) . https://dx.doi.org/10.2174/157340641303170410181557
DOI https://dx.doi.org/10.2174/157340641303170410181557 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
17
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Molecular Docking and Spectroscopic Methods for Investigation of The Interaction Between Regorafenib with Human Serum Albumin (HSA) and Calf Thymus DNA (Ct-DNA) In The Presence Of Different Site Markers
Protein & Peptide Letters The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy
Current Drug Targets Pharmacogenetics and the Pharmaceutical Industry
Current Pharmaceutical Design Integrins: A Method of Early Intervention in the Treatment of Colorectal Liver Metastases
Current Pharmaceutical Design ICG-001, A Novel Small Molecule Regulator of TCF/β-Catenin Masakatsu Transcription
Medicinal Chemistry Effects of Liver Diseases on Drug-metabolizing Enzymes: Implications for Drug Fate Alterations and Nano-therapeutic Openings
Current Medicinal Chemistry Preclinical Drug Discovery in Colorectal Cancer: A Focus on Natural Compounds
Current Drug Targets mRNA as a Versatile Tool for Exogenous Protein Expression
Current Gene Therapy Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization
Current Clinical Pharmacology IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets Molecular Surgery with Auger Electron-Emitting Radiopharmaceuticals
Current Radiopharmaceuticals Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy
Recent Patents on Anti-Cancer Drug Discovery Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors
Current Bioinformatics Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy
Current Medicinal Chemistry Immunogenicity of a Multiepitope Plasmid DNA Encoding T and B Lymphocyte Epitopes from Latent Membrane Protein 2 (LMP2) of Epstein-Barr Virus as a Vaccine in Mice
Protein & Peptide Letters Cucurbitacin B Enhances the Anticancer Effect of Imatinib Mesylate Through Inhibition of MMP-2 Expression in MCF-7 and SW480 Tumor Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Editorial [Human Methylome Variation and the Rise of Epigenetic Epidemiology]
Current Pharmacogenomics and Personalized Medicine Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Flavonoids as Anticancer Agents: Structure-Activity Relationship Study
Current Medicinal Chemistry - Anti-Cancer Agents